Finally, lazertinib received its first approval from the Korea Food and Drug Administration (KFDA) for the treatment of locally advanced or metastatic NSCLC patients with the T790M mutation who were pretreated with EGFR-TKIs in January 2021 [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.